Procoagulant therapeutics in liver disease: a critique and clinical rationale. - sprookjes - yvandenbroek - TriplyDB

Procoagulant therapeutics in liver disease: a critique and clinical rationale.

Procoagulant therapeutics in liver disease: a critique and clinical rationale.

http://www.wikidata.org/entity/Q30458618

about

Outcomes of abdominal surgery in patients with liver cirrhosis Risk of Bleeding in End-Stage Liver Disease Patients Undergoing Cardiac Catheterization Management options in decompensated cirrhosis Changing Concepts of Cirrhotic Coagulopathy.Preoperative Thromboelastometry as a Predictor of Transfusion Requirements during Adult Living Donor Liver Transplantation Thromboelastography: A Practice Summary for Nurse Practitioners Treating Hemorrhage Retrospective review of Prothrombinex use by SAAS MedSTAR.Profiling clinical platelet and plasma use to inform blood supply and contingency planning: PUPPY, the prospective utilization of platelets and plasma study.How do we transfuse blood components in cirrhotic patients undergoing gastrointestinal procedures?Thromboelastography in Dogs with Chronic Hepatopathies.Four-Factor Prothrombin Complex Concentrate for Coagulopathy Reversal in Patients With Liver Disease.Coagulation in chronic liver disease and the use of prothrombin complex concentrate for an emergent procedure: a case report and review of literature.

P2860

Q26766070-7611A669-2691-46BD-AFBC-25B88EE29D77 Q26778667-8BC1CB61-3CF7-4C61-9E26-0FF803A55488 Q26800238-0289E31F-3548-4CCC-AC01-C8F96B365CCF Q30275544-02A43FA3-415B-4F20-8C57-A23009920486 Q35631323-87FB2BB6-F84E-482E-9145-137618A639DD Q35926609-B178B7DC-23CA-4765-BE15-9525A48B53E3 Q39016869-A69FED68-53E3-41D3-A733-D2150ED1B58B Q39417906-5159A15E-B3AE-4074-8B94-720B73A38B99 Q39997164-24590714-7D5D-443A-9B8E-1D2F3F9901E4 Q42315920-832B9666-22F9-4DF6-B192-3B30229B4F36 Q45858250-9DCDEE87-7CF9-4420-8F83-B3B9FCDEAABF Q55215705-9D941EB8-9270-4E4D-BA9F-62A1BD881812

P2860

Procoagulant therapeutics in liver disease: a critique and clinical rationale.

http://www.wikidata.org/entity/Q30458618

description

2014 nî lūn-bûn

@nan

2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Procoagulant therapeutics in liver disease: a critique and clinical rationale.

@ast

Procoagulant therapeutics in liver disease: a critique and clinical rationale.

@en

type

label

Procoagulant therapeutics in liver disease: a critique and clinical rationale.

@ast

Procoagulant therapeutics in liver disease: a critique and clinical rationale.

@en

prefLabel

Procoagulant therapeutics in liver disease: a critique and clinical rationale.

@ast

Procoagulant therapeutics in liver disease: a critique and clinical rationale.

@en

P1433

Q30458618-AE92A1E7-FC0A-4369-BA12-F7DF31F40E71

P1476

Q30458618-8548C465-FE49-4CDA-9DDB-DB5D590BB30B

P2093

Q30458618-47382E96-F884-4778-8938-199D9C7B1875

Q30458618-6DA31825-589A-403F-BC2B-1CCE9D71E636

Q30458618-C82988A6-4ABF-474B-9B17-A0B36CC4DF92

Q30458618-D8A29400-EA3B-466A-B757-B18E91BD5A81

P2860

Q30458618-031DC446-28E5-4994-AD4F-2A980148B484

Q30458618-047CF9D2-4D61-4882-A6DB-0FA136D914F1

Q30458618-092F8A27-434F-4092-BF56-A26B81844C86

Q30458618-0BB4EA73-131A-4B09-94AC-5EFA04253A45

Q30458618-0D7294D5-DA18-48B2-AE7F-57B8816AB860

Q30458618-0FD0252F-5FA1-45A7-9EA5-5286F96A668F

Q30458618-10B51827-3227-41A5-B333-A403570518D4

Q30458618-1E439E00-B265-4E2D-9CB2-F668402B57E9

Q30458618-1F625431-6BF0-4FC4-92CD-72D4751D83E0

Q30458618-1F75D32E-7D3C-4FC2-BF0C-0D6CAD927038

P2888

Q30458618-5A79DC3D-6246-43AD-A143-52B47ED26BB6

P304

Q30458618-DC616DB6-3552-428D-9507-343170514DF2

P31

Q30458618-9B47C723-D7F1-4DE8-9AF2-7988463F31F1

P356

Q30458618-766D9456-AD76-4147-A373-C3AAB83AA9F6

P407

Q30458618-DD6C7239-3726-4946-8729-48C8020A9CBB

P433

Q30458618-7B77F65D-C1BB-4B7D-B42F-95AFB84E95DD

P478

Q30458618-2D47E997-D27D-459C-ADC1-876FB9B0C1B1

P50

Q30458618-C2F50DAB-CD8B-4159-B189-D75D96199142

P577

Q30458618-C2D63DAA-23A7-4D8A-803F-5CFE49AAB5BE

P698

Q30458618-1C989EF2-B7F8-44F4-83DB-8E1BAA35B4D7

P356

NRGASTRO.2014.121

P1433

Nature Reviews Gastroenterology & Hepatology

P1476

Procoagulant therapeutics in liver disease: a critique and clinical rationale

@en

P2093

Curtis K Argo

http://www.w3.org/2001/XMLSchema#string

Neeral L Shah

http://www.w3.org/2001/XMLSchema#string

Patrick G Northup

http://www.w3.org/2001/XMLSchema#string

Stephen H Caldwell

http://www.w3.org/2001/XMLSchema#string

P2860

Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines

Recombinant activated factor VII for coagulopathy in fulminant hepatic failure compared with conventional therapy.

Recombinant activated factor VII (rFVIIa) as a hemostatic agent in liver disease: a break from convention in need of controlled trials.

Coagulopathy does not fully protect hospitalized cirrhosis patients from peripheral venous thromboembolism.

Blood products, volume control, and renal support in the coagulopathy of liver disease.

Coagulation in liver disease: a guide for the clinician.

Hepatic vein pressure gradient reduction and prevention of variceal bleeding in cirrhosis: a systematic review.

Platelet dysfunction in renal failure.

Thrombin generation in patients with cirrhosis: the role of platelets.

Incidence of bleeding following invasive procedures in patients with thrombocytopenia and advanced liver disease.

P2888

nrgastro.2014.121

P304

675-682

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NRGASTRO.2014.121

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P50

Nicolas Intagliata

P577

2014-07-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25023035

http://www.w3.org/2001/XMLSchema#string